Fluxion Biosciences, Inc. announced the release of a new reagent kit for the IsoFlux System designed to provide more options for circulating tumor cell (CTC) and other rare cell capture from biological samples. The IsoFlux Rare Cell Enrichment (Streptavidin) Kit incorporates streptavidin-coated magnetic beads that can bind with one or more biotinylated antibodies targeted towards cell-surface markers on the cells of interest. This new kit facilitates capture of targeted rare cell populations that can include: CTCs, cells undergoing epithelial to mesenchymal transition (EMT), cells expressing a particular drug or disease target, stem cells, and immune cells.
Similar to the existing IsoFlux enrichment kits, the IsoFlux Rare Cell Enrichment (Streptavidin) Kit utilizes an advanced microfluidic technology to achieve targeted, high sensitivity rare cell capture. The cells collected with this kit are immediately ready for downstream analysis, including qPCR (gene expression, genotyping), next-generation sequencing (NGS), and immunofluorescence imaging. The samples are optimized for molecular analysis and feature high cell recovery, minimal background cells, and low-volume elution.
"The IsoFlux System has been adopted by labs across the world that continue to identify new applications," said Michael Schwartz, Program Director. "Many of these new applications benefit from the well understood and utilized streptavidin-biotin chemistry. This new kit provides a simple, off-the-shelf reagent kit that can target a wide variety of cell types using familiar chemistry."
The IsoFlux Rare Cell Enrichment (Streptavidin) Kit is available immediately.
